Regeneron Pharmaceuticals, Inc. (REGN)

US — Healthcare Sector
Peers: CRSP  NVO  SRPT  NTLA  INCY  ALNY  UTHR  RARE  APLS  PTCT  RETA  ICPT  KRYS  MDGL  BGNE  BMRN  IMGN  RXDX  ARWR  IONS 

Automate Your Wheel Strategy on REGN

With Tiblio's Option Bot, you can configure your own wheel strategy including REGN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol REGN
  • Rev/Share 132.0122
  • Book/Share 275.4227
  • PB 1.8647
  • Debt/Equity 0.092
  • CurrentRatio 4.9267
  • ROIC 0.1024

 

  • MktCap 54515489840.0
  • FreeCF/Share 28.3046
  • PFCF 18.0509
  • PE 12.1794
  • Debt/Assets 0.072
  • DivYield 0.0034
  • ROE 0.1477

 

  • Rating A
  • Score 4
  • Recommendation Buy
  • P/E Score 2
  • DCF Score 5
  • P/B Score 3
  • D/E Score 3

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Downgrade REGN RBC Capital Mkts Outperform Sector Perform -- $662 May 30, 2025
Downgrade REGN Wells Fargo Overweight Equal Weight -- $580 May 30, 2025
Upgrade REGN Citigroup Neutral Buy -- $700 May 14, 2025
Resumed REGN Cantor Fitzgerald -- Overweight -- $695 April 22, 2025
Upgrade REGN Leerink Partners Market Perform Outperform $762 $834 Feb. 5, 2025
Downgrade REGN UBS Buy Neutral $1130 $738 Jan. 16, 2025
Resumed REGN BofA Securities -- Underperform -- $565 Dec. 10, 2024
Downgrade REGN Leerink Partners Outperform Market Perform $1175 $1077 Sept. 24, 2024

News

Sanofi & Regeneron's Dupixent Gets FDA Nod for Bullous Pemphigoid
REGN, SNY
Published: June 20, 2025 by: Zacks Investment Research
Sentiment: Positive

SNY and REGN's Dupixent gets FDA approval for a rare and chronic skin disease, marking its eighth approved indication for the drug.

Read More
image for news Sanofi & Regeneron's Dupixent Gets FDA Nod for Bullous Pemphigoid
Regeneron CEO on 23andMe bid: Trying to balance individual privacy with biotech & genetics research
MEHCQ, REGN
Published: June 11, 2025 by: CNBC Television
Sentiment: Neutral

Regeneron founder, chairman and CEO Dr. Leonard Schleifer joins 'Squawk Box' to discuss the company's bid for 23andMe, privacy concerns over 23andMe's genetic data, importance of biotechnology, and more.

Read More
image for news Regeneron CEO on 23andMe bid: Trying to balance individual privacy with biotech & genetics research
Regeneron Pharmaceuticals, Inc. (REGN) Presents at 46th Annual Goldman Sachs Global Healthcare Conference Transcript
REGN
Published: June 09, 2025 by: Seeking Alpha
Sentiment: Neutral

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN ) 46th Annual Goldman Sachs Global Healthcare Conference June 9, 2025 10:40 AM ET Company Participants Christopher R. Fenimore - Executive VP of Finance & CFO Ryan Crowe - Senior Vice President of Investor Relations & Strategic Analysis Conference Call Participants Salveen Jaswal Richter - Goldman Sachs Group, Inc., Research Division Salveen Jaswal Richter Great.

Read More
image for news Regeneron Pharmaceuticals, Inc. (REGN) Presents at 46th Annual Goldman Sachs Global Healthcare Conference Transcript
REGN Strengthens Obesity Pipeline: Will the Move Revive the Stock?
REGN
Published: June 05, 2025 by: Zacks Investment Research
Sentiment: Positive

REGN inks a $2B-plus obesity drug deal with Hansoh, aiming to expand its pipeline amid slumping Eylea sales and pipeline setbacks.

Read More
image for news REGN Strengthens Obesity Pipeline: Will the Move Revive the Stock?
Why Regeneron Is Falling And Why You Should Avoid It
REGN
Published: June 04, 2025 by: Benzinga
Sentiment: Negative

Regeneron Pharmaceuticals (REGN) has been in a persistent downtrend for over 280 days. The stock is currently in the 10th Phase of its 18-Phase Adhishthana Cycle, our proprietary cyclical framework.

Read More
image for news Why Regeneron Is Falling And Why You Should Avoid It
REGN Stock Undervalued At $500?
REGN
Published: June 02, 2025 by: Forbes
Sentiment: Negative

Regeneron Pharmaceuticals (NASDAQ:REGN) shares witnessed a notable 19% decline on Friday, May 30, in the wake of the unexpected failure of itepekimab, its chronic obstructive pulmonary disease (COPD) treatment in conjunction with Sanofi, during a late-stage clinical trial. One of the two trials did not achieve its primary endpoint, which is a significant setback considering that itepekimab was anticipated to become a blockbuster drug, with peak sales projections from Sanofi estimated between $2 billion and $6 billion.

Read More
image for news REGN Stock Undervalued At $500?
Regeneron's weight-loss drug helps preserve muscle mass in study
REGN
Published: June 02, 2025 by: Reuters
Sentiment: Positive

Regeneron Pharmaceuticals said on Monday its experimental weight-loss drug combination helped preserve muscle mass in a mid-stage study.

Read More
image for news Regeneron's weight-loss drug helps preserve muscle mass in study
Regeneron Expands Clinical-Stage Obesity Portfolio with Strategic In-Licensing of Novel Dual GLP-1/GIP Receptor Agonist
REGN
Published: June 02, 2025 by: GlobeNewsWire
Sentiment: Neutral

New licensing agreement with Hansoh Pharma provides Regeneron with HS-20094, a GLP-1/GIP receptor agonist in advanced stages of clinical development in China

Read More
image for news Regeneron Expands Clinical-Stage Obesity Portfolio with Strategic In-Licensing of Novel Dual GLP-1/GIP Receptor Agonist
S&P 500 Gains & Losses Today: Ulta Beauty Stock Soars; Regeneron Shares Plummet
REGN, ULTA
Published: May 30, 2025 by: Investopedia
Sentiment: Neutral

Major U.S. equities indexes were mixed in the final session of the holiday-shortened trading week as President Donald Trump reverted to an antagonistic tone on trade with China and the latest Personal Consumption Expenditures data showed that inflation fell more than expected in April.

Read More
image for news S&P 500 Gains & Losses Today: Ulta Beauty Stock Soars; Regeneron Shares Plummet
Regeneron dashes Wall Street's hopes as COPD treatment trial suffers a failure
REGN
Published: May 30, 2025 by: Market Watch
Sentiment: Negative

Regeneron's stock is having its worst day in 14 years after the failure of late-stage trial of its COPD treatment, after analysts had just placed a high probability of a positive result.

Read More
image for news Regeneron dashes Wall Street's hopes as COPD treatment trial suffers a failure
Itepekimab Failure A Setback For Sanofi And Regeneron
REGN, SNY
Published: May 30, 2025 by: Seeking Alpha
Sentiment: Negative

Itepekimab's inconsistent phase 3 results represent a setback for Regeneron Pharmaceuticals and Sanofi. The results do not support regulatory submissions and a 3-4 year approval delay, and lower peak sales potential looks like a best-case scenario for itepekimab. Regeneron faces a greater impact, as it is losing an important growth driver in the second half of the decade.

Read More
image for news Itepekimab Failure A Setback For Sanofi And Regeneron
Regeneron shares plunge after mixed COPD drug trial results
REGN
Published: May 30, 2025 by: Proactive Investors
Sentiment: Negative

Shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) sank nearly 19% on Friday after the company's experimental COPD drug, developed with partner Sanofi SA (ADR) (NYSE:SNY), posted mixed results in two Phase 3 trials—casting doubt on its regulatory path and delaying hopes for a major new revenue stream. The drug, itepekimab, reduced moderate or severe flare-ups by 27% compared to placebo over 52 weeks in the AERIFY-1 study, which enrolled 1,127 former smokers with chronic obstructive pulmonary disease (COPD).

Read More
image for news Regeneron shares plunge after mixed COPD drug trial results
Regeneron, SNY Report Mixed Results From Late-Stage COPD Studies
REGN, SNY
Published: May 30, 2025 by: Zacks Investment Research
Sentiment: Neutral

Regeneron and SNY's itepekimab meets the primary endpoint in one COPD trial but misses in another, leaving future plans under review.

Read More
image for news Regeneron, SNY Report Mixed Results From Late-Stage COPD Studies
Linvoseltamab in Combination with Carfilzomib or Bortezomib Shows Promising Initial Results in Earlier Lines of Treatment for Relapsed/Refractory Multiple Myeloma
REGN
Published: May 22, 2025 by: GlobeNewsWire
Sentiment: Neutral

First results to be presented in two ASCO oral presentations Data in both combinations demonstrate high response rates TARRYTOWN, N.Y., May 22, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced initial results from two cohorts of the Phase 1b LINKER-MM2 trial evaluating linvoseltamab in combination with two different proteasome inhibitors (PI) – carfilzomib or bortezomib – in patients with relapsed/refractory (R/R) multiple myeloma (MM).

Read More
image for news Linvoseltamab in Combination with Carfilzomib or Bortezomib Shows Promising Initial Results in Earlier Lines of Treatment for Relapsed/Refractory Multiple Myeloma
Regeneron's 23andMe Steal: Smart Genetics Play That Won't Cure Near-Term Growth Pains
MEHCQ, REGN
Published: May 21, 2025 by: Seeking Alpha
Sentiment: Neutral

Regeneron acquired 23andMe for $256M, gaining 15M DNA profiles to enhance R&D, but the benefits are years away and the risks are immediate. Eylea franchise revenues dropped 26% year-over-year as biosimilars entered the market, stalling overall company growth. Dupixent continues strong growth with new approvals in COPD and CSU, keeping Regeneron profitable despite challenges.

Read More
image for news Regeneron's 23andMe Steal: Smart Genetics Play That Won't Cure Near-Term Growth Pains
Regeneron Pharmaceuticals, Inc. (REGN) RBC Capital Markets Global Healthcare Conference (Transcript)
REGN
Published: May 20, 2025 by: Seeking Alpha
Sentiment: Neutral

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN ) RBC Capital Markets Global Healthcare Conference May 20, 2025 11:00 AM ET Company Participants Mark Hudson - Senior Director of Investor Relations George D. Yancopoulos - Board Co-Chair, President and Chief Scientific Officer Conference Call Participants Brian Abrahams - RBC Capital Markets Brian Abrahams Our next featured company, Regeneron, has always been known for its R&D engine.

Read More
image for news Regeneron Pharmaceuticals, Inc. (REGN) RBC Capital Markets Global Healthcare Conference (Transcript)
REGN Signs $256M Buyout Deal With 23andMe to Boost Genomics Research
REGN
Published: May 20, 2025 by: Zacks Investment Research
Sentiment: Positive

Regeneron is set to acquire 23andMe assets for $256 million to boost genetic drug discovery. The transaction is expected to close by third-quarter 2025.

Read More
image for news REGN Signs $256M Buyout Deal With 23andMe to Boost Genomics Research
Regeneron Buys 23andMe in Bankruptcy Auction
REGN
Published: May 19, 2025 by: Investopedia
Sentiment: Negative

Regeneron Pharmaceuticals (REGN) agreed to buy DNA testing company 23andMe for $256 million in a bankruptcy court auction, the company said Monday.

Read More
image for news Regeneron Buys 23andMe in Bankruptcy Auction
Regeneron Pharmaceuticals to buy 23andMe for $256M — taking control of genetic data of millions
REGN
Published: May 19, 2025 by: New York Post
Sentiment: Negative

It will acquire genetic data of more than 15 million customers – raising privacy concerns from individuals who had willingly handed over the samples to completely different owners.

Read More
image for news Regeneron Pharmaceuticals to buy 23andMe for $256M — taking control of genetic data of millions
Regeneron Pharmaceuticals to buy bankrupt 23andMe in $256M deal
MEHCQ, REGN
Published: May 19, 2025 by: Fox Business
Sentiment: Neutral

Genetic testing company 23andMe filed for Chapter 11 bankruptcy protection in March. Regeneron Pharmaceuticals announced it would buy "substantially all" of 23andMe's assets.

Read More
image for news Regeneron Pharmaceuticals to buy bankrupt 23andMe in $256M deal
Pharma giant Regeneron to buy 23andMe and its customers' data for $256M
MEHCQ, REGN
Published: May 19, 2025 by: TechCrunch
Sentiment: Neutral

Pharmaceutical maker Regeneron announced Monday it will buy genetic testing company 23andMe for $256 million following a bankruptcy auction.

Read More
image for news Pharma giant Regeneron to buy 23andMe and its customers' data for $256M
Cramer's Stop Trading: Regeneron
REGN
Published: May 19, 2025 by: CNBC Television
Sentiment: Neutral

Jim Camer breaks down why he's keeping an eye on shares of Regeneron.

Read More
image for news Cramer's Stop Trading: Regeneron
Regeneron Pharmaceuticals to buy 23andMe and its data for $256 million
MEHCQ, REGN
Published: May 19, 2025 by: CNBC
Sentiment: Neutral

Regeneron Pharmaceuticals is acquiring "substantially all" of 23andMe's assets for $256 million following a bankruptcy auction. The drugmaker is buying 23andMe's Personal Genome Service, Total Health and Research Services business lines, but not its telehealth subsidiary Lemonaid Health.

Read More
image for news Regeneron Pharmaceuticals to buy 23andMe and its data for $256 million
Regeneron to buy 23andMe out of bankruptcy for $256m
MEHCQ, REGN
Published: May 19, 2025 by: Proactive Investors
Sentiment: Neutral

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) has agreed to buy genetic testing company 23andMe for $256 million, two months after the biotech firm filed for Chapter 11 bankruptcy. The deal includes 23andMe's consumer DNA testing and health research services, but excludes its telehealth arm, Lemonaid Health, which is being shut down.

Read More
image for news Regeneron to buy 23andMe out of bankruptcy for $256m
23andMe sells its most valuable asset. Regeneron promises keep your DNA private.
MEHCQ, REGN
Published: May 19, 2025 by: Market Watch
Sentiment: Negative

Regeneron said it will continue uninterrupted service of 23andMe's consumer genome services — such as connecting with living relatives with shared DNA — after its purchase closes as expected in the third quarter of this year.

Read More
image for news 23andMe sells its most valuable asset. Regeneron promises keep your DNA private.
Regeneron to Buy 23andMe Out of Bankruptcy for $256 Million
MEHCQ, REGN
Published: May 19, 2025 by: WSJ
Sentiment: Positive

Regeneron Pharmaceuticals said it will acquire substantially all of 23andMe's assets for $256 million after coming out on top at a bankruptcy auction for the once-sizzling DNA-testing startup.

Read More
image for news Regeneron to Buy 23andMe Out of Bankruptcy for $256 Million
Regeneron to buy bankrupt genetic testing firm 23andMe for $256 million
MEHCQ, REGN
Published: May 19, 2025 by: Reuters
Sentiment: Negative

Drugmaker Regeneron Pharmaceuticals will buy genetic testing firm 23andMe Holding for $256 million through a bankruptcy auction, the companies said on Monday.

Read More
image for news Regeneron to buy bankrupt genetic testing firm 23andMe for $256 million
Regeneron Enters into Asset Purchase Agreement to Acquire 23andMe® for $256 Million; Plans to Maintain Consumer Genetics Business and Advance Shared Goals of Improving Human Health and Wellness
REGN
Published: May 19, 2025 by: GlobeNewsWire
Sentiment: Neutral

Purchase is subject to bankruptcy court and regulatory approvals Regeneron will prioritize the privacy, security and ethical use of 23andMe's customer data; stands ready to work with independent, court-appointed Customer Privacy Ombudsman Planned purchase to strengthen Regeneron's ongoing leadership in genetics-guided research and drug development to help people with serious diseases TARRYTOWN, N.Y., May 19, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced it has been named the successful bidder in the bankruptcy auction for substantially all of the assets of 23andMe Holding Co., a leading human genetics and biotechnology company.

Read More
image for news Regeneron Enters into Asset Purchase Agreement to Acquire 23andMe® for $256 Million; Plans to Maintain Consumer Genetics Business and Advance Shared Goals of Improving Human Health and Wellness
75th Annual Regeneron International Science and Engineering Fair Awards Teen Scientists from Around the World More Than $9 Million in 2025 Competition
REGN
Published: May 16, 2025 by: GlobeNewsWire
Sentiment: Neutral

Adam Kovalčík , 19, receives $100,000 Top Award for his development of a medicine that can stop viruses from copying genes and controlling infections at the world's largest pre-college STEM competition in Columbus, Ohio

Read More
image for news 75th Annual Regeneron International Science and Engineering Fair Awards Teen Scientists from Around the World More Than $9 Million in 2025 Competition
Regeneron Prevails over Amgen in Antitrust PCSK9 Lawsuit Protecting Biotech Innovation and Patient Access to Life-Saving Treatments
REGN
Published: May 15, 2025 by: GlobeNewsWire
Sentiment: Neutral

Federal court jury found Amgen liable for violating antitrust and tort laws by using cross-therapeutic bundled rebates to prevent Praluent ® (alirocumab) from competing in the market

Read More
image for news Regeneron Prevails over Amgen in Antitrust PCSK9 Lawsuit Protecting Biotech Innovation and Patient Access to Life-Saving Treatments

About Regeneron Pharmaceuticals, Inc. (REGN)

  • IPO Date 1991-04-02
  • Website https://www.regeneron.com
  • Industry Biotechnology
  • CEO Dr. Leonard S. Schleifer M.D., Ph.D.
  • Employees 15158

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.